The peptide's ability to simultaneously modulate multiple pathways involved in tissue repair and cellular protection distinguishes it from single-target therapeutic agents and may explain its consistent benefits across diverse injury models
It is important to note that telogen effluvium is not specific to GLP-1 agonists but can occur with any form of rapid weight loss
Clinical trials Real-world outcomes are consistent with randomised controlled trials: Eli Lillys SURPASS-CVOT programme confirmed Tirzepatide significantly reduces cardiovascular events in high-risk patients
We hypothesized that allulose supplementation would lead to significant improvements in body weight, insulin sensitivity, and glycemic control compared to control animals fed a standard diet without allulose
Age is not a barrier to GLP-1 therapy, but individual health status, medication interactions, and metabolic needs require personalized evaluation
DNADeoxyribonucleic acid (DNA) is a molecule found in the chromosomes that carries genetic information